PCPC: 'Double Fees' For Cosmetic-Drug Products Are Regulatory Reform Concern
This article was originally published in The Rose Sheet
Cosmetic products containing OTC drug ingredients – such as acne-fighting agents and UV filters in skin-care and makeup items, fluoride in toothpaste and dandruff medication in shampoo – could be subject to multiple fees if FDA's concept for generating OTC monograph program funding were to become a reality along with the Personal Care Products Safety Act.
You may also be interested in...
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.
The agency’s committees for Risk Assessment and Socio-Economic Analysis will check comments and take relevant evidence-based information into consideration as they develop their opinions. Final opinions will be delivered to the European Commission “in the shortest possible timeframe,” ECHA says.
One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.